Blogs, insights, guides and videos on India's unlisted market — all in one place.
<p>Jupiter International’s latest results show sharp profit growth backed by a massive solar capacity expansion. In this video, we break down its FY25 performance, upcoming scale-up plans, ValueQuest’s backing, and why the stock is valued as a future growth story rather than a bargain.</p>
<p>Edelweiss Financial Services has sold <strong>10% of Edelweiss Asset Management (AMC)</strong> to <strong>WestBridge Capital</strong>, as part of a larger transaction that values the AMC at <strong>~₹3,000 crore</strong>. WestBridge will eventually acquire <strong>up to 15% for ₹450 crore</strong>, with the remaining stake to be transferred by <strong>March 2026</strong>.</p> <p>The real question: <strong>Is this valuation justified given Edelweiss AMC’s AUM and profitability?</strong></p> <h2>What exactly happened?</h2> <ul data-spread="false"> <li> <p><strong>Date of transfer:</strong> 17 December</p> </li> <li> <p><strong>Stake sold:</strong> 10% (additional 5% to follow)</p> </li> <li> <p><strong>Buyers:</strong> WestBridge affiliates — Setu AIF Trust, Konark Trust, MMPL Trust</p> </li> <li> <p><strong>Regulatory approvals:</strong></p> <ul data-spread="false"> <li> <p>CCI: 21 October</p> </li> <li> <p>SEBI: 12 November</p> </li> </ul> </li> <li> <p><strong>Investor exit window:</strong> Closed on 2 December</p> </li> </ul> <p>This was a fully regulator-approved transaction with no structural surprises.</p> <h2>Financials Performance in Crores</h2> <h2><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1767701561.jpg" alt="" width="50%" /></h2> <h2>Key numbers at a glance</h2> <h2><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1767701593.jpg" alt="" width="50%" /></h2> <h2>Why WestBridge is interested</h2> <p>WestBridge manages <strong>$7+ billion in AUM globally</strong> and typically invests in:</p> <ul data-spread="false"> <li> <p>Scaled financial platforms</p> </li> <li> <p>Predictable cash-generating businesses</p> </li> <li> <p>Long-term structural growth stories</p> </li> </ul> <p>Edelweiss AMC fits this profile well:</p> <ul data-spread="false"> <li> <p>Profitable asset management platform</p> </li> <li> <p>Strong equity AUM growth</p> </li> <li> <p>Diversified products (Mutual Funds, AIFs, PMS)</p> </li> <li> <p>Operating leverage beginning to reflect in profits</p> </li> </ul> <p>In simple terms, WestBridge is backing <strong>India’s rising equity participation trend</strong>.</p> <h2>The valuation debate: Is 57x P/E too expensive?</h2> <h3>Re-rating the deal with FY26E PAT of ₹90 crore</h3> <p>The initial narrative around the deal focused on a <strong>~57x P/E</strong>, derived from <strong>FY25 PAT of ₹53 crore</strong>. However, management guidance and operating leverage point to a <strong>FY26E PAT of ~₹90 crore</strong>, which meaningfully changes the valuation picture.</p> <p><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1767701614.jpg" alt="" width="50%" /></p> <p>At <strong>~33x FY26E earnings</strong>, Edelweiss AMC no longer looks expensive. Instead, it starts to look <strong>undervalued relative to listed peers</strong>, especially given its growth trajectory.</p> <h2>Industry comparison: How Edelweiss stacks up against listed AMCs</h2> <p>A forward-looking comparison puts the valuation into sharper context.</p> <p><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1767701632.jpg" alt="" width="50%" /></p> <p><strong>What stands out:</strong></p> <ul data-spread="false"> <li> <p>Edelweiss AMC trades at the moderate forward P/E of 33x among major peers</p> </li> <li> <p>Larger AMCs enjoy scale stability, yet command 2<strong>0–40x forward earnings</strong></p> </li> <li> <p>Edelweiss, despite smaller AUM, is growing <strong>faster in equity assets</strong>, justifying convergence in multiples over time</p> </li> </ul> <p>This comparison strongly suggests that <strong>WestBridge entered at a conservative forward multiple</strong>.</p> <h2>AUM-based sanity check (the more relevant lens)</h2> <p>AMCs are often valued as a <strong>percentage of Assets Under Management</strong>, not just earnings.</p> <h2><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1767701652.jpg" alt="" width="50%" /></h2> <h2>Is the ₹3,000 crore valuation justified?</h2> <p>Looking at the deal through multiple lenses, the answer increasingly tilts towards <strong>yes</strong>.</p> <h3>1. Forward earnings justify the price</h3> <p>At a valuation of <strong>₹3,000 crore</strong> and <strong>FY26E PAT of ₹90 crore</strong>, Edelweiss AMC is valued at <strong>~33x forward earnings</strong>. This is:</p> <ul data-spread="false"> <li> <p>Lower than all listed peers in the industry comparison</p> </li> <li> <p>Conservative for a business delivering <strong>30%+ equity AUM growth</strong></p> </li> </ul> <p>In effect, WestBridge is paying <strong>less for future profits</strong> than what the market assigns to mature AMCs today.</p> <h3>2. AUM-based valuation is within comfort zone</h3> <p>Within the industry's standard valuation range of 5-15% of AUM, Edelweiss AMC sits at ~1.9%, compared to HDFC AMC's ~8% valuation on its ₹12 lakh crore AUM with a Market Capitalization of More than 1 lakh Crore.</p> <p><br />Given Edelweiss AMC increasing equity mix and improving margins, a move towards the upper end of this band over time is plausible. </p> <h3>3. Scale-up optionality is not fully priced in</h3> <p>Despite strong growth, Edelweiss AMC operates at a <strong>much smaller scale</strong> than peers. As AUM scales up:</p> <ul data-spread="false"> <li> <p>Fixed costs flatten</p> </li> <li> <p>Margins expand</p> </li> <li> <p>PAT compounds faster than AUM</p> </li> </ul> <p>The current valuation does <strong>not fully price in this operating leverage</strong>.</p> <h3>4. Downside protection for the buyer</h3> <p>Even if growth moderates, the entry multiple of <strong>~33x FY26E</strong> relative to peers trading at <strong>20–40x</strong>. This asymmetry—limited downside, meaningful upside—makes the valuation attractive for a long-term investor.</p> <h3>Why Edelweiss chose to sell now</h3> <p>This deal is not a full exit—it is <strong>strategic monetisation</strong>.</p> <p><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1767701671.jpg" alt="" width="50%" /></p> <p>Edelweiss is effectively <strong>reducing risk while retaining upside</strong>.</p> <h2>Why WestBridge is comfortable paying up</h2> <p>WestBridge is not buying current earnings—it is buying:</p> <ul data-spread="false"> <li> <p>Sustained equity AUM growth</p> </li> <li> <p>Margin expansion as scale improves</p> </li> <li> <p>Future earnings compounding</p> </li> </ul> <h2>Final verdict: Reasonable or not?</h2> <h3><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1767701693.jpg" alt="" width="50%" /></h3> <h3>Bottom line</h3> <p>This is not a bargain deal. It is a <strong>growth-priced, conviction-led transaction</strong>.</p> <p>Edelweiss monetised its AMC at the right time.<br />WestBridge is betting that <strong>India’s asset management growth runway is far from over</strong>.</p> <p>In asset management, <strong>AUM growth—not current profits—ultimately decides who’s right</strong>.</p>
<div id="shorts-panel-container" class="style-scope ytd-shorts"> <div id="anchored-panel" class="anchored-panel style-scope ytd-shorts"> <div id="content" class="style-scope ytd-engagement-panel-section-list-renderer"> <div id="items" class="style-scope ytd-structured-description-content-renderer"> <div id="snippet" class="style-scope ytd-text-inline-expander"><span id="snippet-text" class="style-scope ytd-text-inline-expander"><span id="plain-snippet-text" class="style-scope ytd-text-inline-expander">Explosive growth, widening losses, and a critical test for India’s quick-commerce model as Zepto heads toward the public markets.</span></span></div> <div id="source-attributions-wrapper" class="style-scope ytd-expandable-video-description-body-renderer"></div> </div> </div> <div id="footer" class="style-scope ytd-engagement-panel-section-list-renderer"></div> </div> </div> <div class="navigation-container style-scope ytd-shorts"> <div id="navigation-button-up" class="navigation-button style-scope ytd-shorts"> <div class="yt-spec-button-shape-next__icon" aria-hidden="true"> <div> </div> </div> </div> </div>
<p>Is video mein hum ESDS aur OYO ke IPO journey ko cover karte hain. Dono unlisted companies alag sectors se hain, lekin common factor hai profitability. ESDS ko SEBI approval mil chuka hai aur OYO ne strong turnaround dikhaya hai. Ye IPO wave hype nahi, balki quality aur sustainable earnings par based hai. </p>
<h2>Overview</h2> <p>Kanara Consumer Products Limited (formerly known as Kurlon Limited) is conducting an ExtraOrdinary General Meeting on January 20, 2026, to approve a merger of its two wholly-owned subsidiaries into the parent company.</p> <h2>Why the Merger is Happening</h2> <h3>Strategic Rationale</h3> <h4>1. Post-Kurlon Brand Sale Repositioning</h4> <p>After selling the iconic ‘KURLON’ brand, Kanara Consumer Products has been actively looking to venture into new business activities. The merger of its two subsidiaries is part of this strategic expansion and growth plan.</p> <h4>2. Operational Efficiency & Cost Reduction</h4> <ul data-spread="false"> <li> <p><strong>Economies of scale</strong> through consolidated operations</p> </li> <li> <p><strong>Reduction in overheads –</strong> elimination of duplicate administrative, managerial, and corporate structures</p> </li> <li> <p><strong>Streamlined financial reporting</strong> and centralized management</p> </li> <li> <p><strong>Optimal resource utilization</strong> across the combined entity</p> </li> </ul> <h4>3. Financial Synergies</h4> <ul data-spread="false"> <li> <p>Leveraging the <strong>strong cash flow </strong>of the parent company to fund the growth of subsidiaries whose cash cycles are less stable</p> </li> <li> <p>Better access to capital markets through a stronger combined balance sheet</p> </li> <li> <p>Simplified investment management</p> </li> </ul> <h4>4. Risk Diversification</h4> <p>By consolidating businesses in different sectors (natural extracts and consultancy/investments), the company aims to create stable revenue streams and reduce business risk.</p> <h2>The Subsidiaries Being Merged</h2> <h3>1. Manipal Natural Private Limited (Transferor Company 1)</h3> <p><strong>Business:</strong> Manufacture and export of herbal and ayurvedic products</p> <ul data-spread="false"> <li> <p>Natural herbal extracts</p> </li> <li> <p>Ayurvedic products for beauty, body care, and medicinal use</p> </li> <li> <p>Cultivation of medicinal plants</p> </li> <li> <p>R&D of herbal and nutraceutical products</p> </li> </ul> <h3>2. Kanara Consulting and Service Management Private Limited (Transferor Company 2)</h3> <p><strong>Business:</strong> Consulting and investment services</p> <ul data-spread="false"> <li> <p>Administration and management consultancy</p> </li> <li> <p>Marketing and organizational advisory</p> </li> <li> <p>Investment company dealing in shares, debentures, and securities</p> </li> </ul> <h2>Merger Structure</h2> <ul data-spread="false"> <li> <p><strong>Type:</strong> Merger by absorption under Section 233 of the Companies Act, 2013</p> </li> <li> <p><strong>Appointed Date:</strong> April 1, 2025</p> </li> <li> <p><strong>Share Exchange Ratio:</strong> None (no new shares issued as both are 100% subsidiaries)</p> </li> <li> <p><strong>Treatment:</strong> All shares of subsidiaries held by the parent will be cancelled and extinguished</p> </li> <li> <p><strong>Dissolution:</strong> Both subsidiaries will be dissolved without winding up</p> </li> </ul> <h2>Financial Position (As of March 31, 2025)</h2> <h3>Kanara Consumer Products Limited (Parent Company)</h3> <p><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1766740890.jpg" alt="" width="50%" /></p> <p><strong>Key Observations:</strong></p> <ul data-spread="false"> <li> <p>Strong cash position with assets of ₹1,378+ crores</p> </li> <li> <p>Highly profitable with ₹86.5 crores net profit</p> </li> <li> <p>Primary income from investments/other income rather than operations</p> </li> </ul> <h3>Manipal Natural Private Limited (Subsidiary 1)</h3> <p><strong>Financials (₹ Lakhs):</strong></p> <p><strong><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1766741277.jpg" alt="" width="50%" /></strong></p> <h3>Kanara Consulting and Service Management Pvt Ltd (Subsidiary 2)</h3> <p><strong>Status:</strong> Loss-making with negative equity due to accumulated losses</p> <p><strong>Financials (₹ Lakhs):</strong></p> <p><strong><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1766741471.jpg" alt="" width="50%" /></strong></p> <h2>Shareholding Pattern</h2> <h3>Promoter Holdings (96.11% – Promoters & Interested Entities)</h3> <p>Ownership Structure: The company is heavily promoter-controlled with the Manipal Group entities holding the dominant stake.</p> <h2><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1766742440.jpg" alt="" width="50%" /></h2> <h2>Business Operations</h2> <h3>Current Business Profile</h3> <p><strong>Kanara Consumer Products Limited:</strong></p> <ul data-spread="false"> <li> <p><strong>Real Estate: </strong>Developers, builders, and managers of immovable properties (lands, buildings, hotels, cold stores)</p> </li> <li> <p><strong>Consumer Goods (Expansion):</strong> Manufacturing and trading in nutrition foods, nutraceutical foods, health foods, beverages, and packaged foods</p> </li> <li> <p><strong>Investment:</strong> Holding shares and securities in other companies</p> </li> <li> <p><strong>Post-Merger Services: </strong>Software development, advertising, and technical consultancy</p> </li> </ul> <h3>Combined Business Post-Merger</h3> <ul data-spread="false"> <li> <p>Herbal and ayurvedic product manufacturing</p> </li> <li> <p>Real estate development and management</p> </li> <li> <p>Consumer goods and nutraceutical foods</p> </li> <li> <p>Business consulting and management services</p> </li> <li> <p>Investment management</p> </li> </ul> <h2>Capital Structure Changes</h2> <h3>Authorized Share Capital Increase</h3> <ul data-spread="false"> <li> <p><strong>Current:</strong> ₹35,00,00,000 (3.5 crores)</p> </li> <li> <p><strong>Post-Merger: </strong>₹40,10,00,000 (4.01 crores)</p> </li> <li> <p><strong>Increase:</strong> ₹5,10,00,000</p> </li> </ul> <p>This increase accommodates the consolidation of business operations.</p> <h2>Expected Impact</h2> <h3>Short-Term Effects</h3> <ul data-spread="false"> <li> <p>Temporary reduction in financial ratios (Net Profit Margin, ROE, EPS, Debt-Equity Ratio) due to absorption of loss-making subsidiaries</p> </li> <li> <p>Integration costs and operational adjustments</p> </li> </ul> <h3>Long-Term Benefits</h3> <ul data-spread="false"> <li> <p><strong>Business diversification</strong> across multiple sectors</p> </li> <li> <p><strong>Operational efficienc</strong>y through consolidated management</p> </li> <li> <p><strong>Cost savings</strong> from elimination of duplicate structures</p> </li> <li> <p><strong>Enhanced growth potential</strong> leveraging the parent’s strong financial position</p> </li> <li> <p><strong>Better market positioning</strong> for new business ventures post-Kurlon brand sale</p> </li> </ul> <h2>Conclusion</h2> <p>The merger is a <strong>strategic restructuring move</strong> by Kanara Consumer Products to consolidate its operations after the sale of the Kurlon brand. While the subsidiaries are currently loss-making with negative equity, the parent company’s strong financial position (₹86.5 crores profit, ₹1,378 crores assets) can absorb these entities and leverage their operational capabilities for future growth in herbal products and consulting services. The merger eliminates corporate redundancies and positions the company for diversified business expansion beyond its traditional mattress business.</p>
<p>Bira 91 showed strong growth from 2015 to 2022–23 and successfully built a national brand in India’s highly regulated beer market. However, weak unit economics hurt profitability, with production costs higher than selling prices. Challenges intensified during IPO preparation when the company converted from private to public, triggering state wise licensing delays of 6 to 7 months. This led to inventory losses of ₹80 to ₹100 crore and rising operational issues. Currently, Bira’s unlisted market valuation is estimated at around ₹1,100 crore.</p>
Indicative prices, company research and your enquiries — in your pocket. Get price notes on the names you follow and reach our team from anywhere.
